The associations of adipokines with selected markers of the renin-angiotensinogen-aldosterone system: the multi-ethnic study of atherosclerosis. by Allison, MA et al.
UC San Diego
UC San Diego Previously Published Works
Title
The associations of adipokines with selected markers of the renin-angiotensinogen-
aldosterone system: the multi-ethnic study of atherosclerosis.
Permalink
https://escholarship.org/uc/item/1qj2j5m1
Journal
Journal of human hypertension, 29(2)
ISSN
0950-9240
Authors
Allison, MA
Jenny, NS
McClelland, RL
et al.
Publication Date
2015-02-01
DOI
10.1038/jhh.2014.40
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
THE ASSOCIATIONS OF ADIPOKINES WITH SELECTED 
MARKERS OF THE RENIN-ANGIOTENSINOGEN-ALDOSTERONE 
SYSTEM: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS
Matthew A. Allison, MD1, Nancy Swords Jenny, PhD2, Robyn L. McClelland, PhD3, Mary 
Cushman, MD2, and Dena Rifkin, MD1,4
1Department of Family and Preventive Medicine, University of California San Diego, La Jolla, CA
2Department of Pathology, University of Vermont College of Medicine, Burlington, VT
3Department of Biostatistics, University of Washington, Seattle, WA
4Department of Medicine, University of California San Diego, La Jolla, CA
Abstract
Among obese individuals, increased sympathetic nervous system activity results in increased renin 
and aldosterone production, as well as renal tubular sodium reabsorption. This study determined 
the associations between adipokines and selected measures of the reninangiotensinogen-
aldosterone system (RAAS). The sample was 1,970 men and women from the Multi-Ethnic Study 
of Atherosclerosis who were free of clinical cardiovascular disease at baseline and had blood 
assayed for adiponectin, leptin, plasma renin activity (PRA) and aldosterone. The mean age was 
64.7 years and 50% were female. The mean (SD) PRA and aldosterone were 1.45 (0.56) ng/ml 
and 150.1 (130.5) pg/ml, respectively. After multivariable adjustment, a 1-SD increment of leptin 
was associated with a 0.55 ng/ml higher PRA and 8.4 pg/ml higher aldosterone (p < 0.01 for both). 
Although adiponectin was not significantly associated with PRA levels, the same increment in this 
adipokine was associated with lower aldosterone levels (−5.5 pg/ml, p = 0.01). Notably, the 
associations between aldosterone and both leptin and adiponectin were not materially changed 
with additional adjustment for PRA. Exclusion of those taking anti-hypertensive medications 
modestly attenuated the associations. The associations between leptin and both PRA and 
aldosterone were not different by gender but were significantly stronger among non-Hispanic 
Whites and Chinese Americans than African and Hispanic Americans (p < 0.01). The findings 
suggest that both adiponectin and leptin may relevant to blood pressure regulation via the RAAS, 
that the associations appear to be robust to anti-hypertension medication use and that the 
associations are likely different by ethnicity.
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INTRODUCTION
Previous studies have demonstrated a robust association between greater adipose tissue and 
higher levels of blood pressure, as well as incident hypertension. Indeed, it is estimated that 
70% of hypertension can be attributed to excess adiposity.1-6 Although undoubtedly a 
multifactorial phenomenon, hypertension in obese individuals has been linked with 
activation of the renin-angiotensinogen-aldosterone system (RAAS) and plasma volume 
expansion.7-10 In this regard, higher sympathetic nervous system (SNS) activity, present in 
obese individuals, results in increased renin release, aldosterone production, and renal 
tubular sodium reabsorption.11-13
The pathophysiologic linkage between higher levels of adipose tissue and increased 
sympathetic nervous system activity is not completely understood. Some have hypothesized 
that cytokines released from adipose tissue, such as adiponectin and/or leptin, may be 
relevant. Indeed, higher leptin has been associated with higher blood pressure levels, as well 
as the prevalence of hypertension, independent of other relevant risk factors including 
obesity.2,6,14 This, combined with findings showing that higher leptin is associated with 
increased SNS activity7,9, suggest that this adipokine may be important in the regulation of 
blood pressure. What is unclear is whether adiponectin and leptin are significantly 
associated with renal and adrenal-specific markers of increased sympathetic nervous system 
activity; namely, plasma renin activity (PRA) and aldosterone, respectively. Therefore, we 
tested the hypothesis that adiponectin and leptin would be significantly associated with 
levels of both PRA and aldosterone, independent of relevant risk factors.
MATERIALS AND METHODS
Participants
The Multi-Ethnic Study of Atherosclerosis (MESA) is a longitudinal cohort study of 
African, Chinese and Hispanic Americans, as well as non-Hispanic Whites. Details about 
the study design have been published.11 In brief, between July 2000 and August 2002 (visit 
1), 6,814 men and women who were 45 to 84 years old and were free of clinically apparent 
cardiovascular disease (CVD) were recruited from 6 United States communities. Individuals 
with a history of physician-diagnosed heart attack, angina, heart failure, stroke or TIA, or 
having undergone an invasive procedure for cardiovascular disease (CABG, angioplasty, 
valve replacement or pacemaker placement) were excluded from participation. Enrolled 
participants returned for follow-up clinic examinations on 3 subsequent examinations (visits 
2, 3 and 4) at approximately 18 to 24-month intervals. All participants provided written 
informed consent and the institutional review boards (IRB) at the participating Universities 
approved the study.
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At clinic visits 2 and 3, a random subsample of 1,970 participants from 5 of the 6 MESA 
field centers enrolled in an ancillary study to determine the presence and extent of calcified 
atherosclerosis in the abdominal aorta using computed tomography.15 The venous blood 
samples taken contemporaneously were subsequently analyzed for selected measures of 
adiposity-associated inflammation, as well as kidney function to include plasma renin 
activity and aldosterone. The data obtained on this subset of participants comprises the 
analytic sample for the current study.
Data Collection
At all clinic visits, standardized questionnaires were used to obtain sociodemographic, race/
ethnicity and health history information. Cigarette smoking was defined as current, former, 
or never. Height and weight were measured with participants wearing light clothing and no 
shoes. Body mass index (BMI) was calculated as weight in kilograms divided by height in 
meters squared. Waist and hip circumferences were measured using a standard flexible tape 
measure. Resting blood pressure was measured 3 times in seated participants with a 
Dinamap model Pro 100 automated oscillometric sphygmomanometer (Critikon). The 
calculation of blood pressure was based on the average of the second and third readings. 
Hypertension (HTN) was defined as systolic blood pressure ≥140 mm Hg, diastolic blood 
pressure ≥ 90 mm Hg, or current use of an antihypertensive medication.
Laboratory
At all clinic examinations, blood samples obtained in the sitting position were obtained after 
a 12-hour fast. Blood was drawn after the participants had been resting in the sitting position 
for about 1 hour. During this time, they did not perform physical activity. Participants were 
instructed to take their usual medications before the clinic visit. Processing of the samples 
began no longer than 30 minutes after the blood draw and the tubes were placed on ice 
during the lag time. Tubes were centrifuged at 4° C at least 2000 g for 15 minutes or 3000 g 
for 10 minutes, for a total of 30,000 g-minutes. Once centrifugation was complete, tubes 
were placed on ice in preparation for pooling and aliquoting. Aliquots were frozen at −70 ° 
C within 10 minutes of preparation.
The blood samples were assayed for total and HDL cholesterol, triglycerides, glucose and 
creatinine levels, as well as measures of systemic inflammation (C-reactive protein, 
fibrinogen, interleukin-6) and insulin concentration.16 Dyslipidemia was defined as a total-
cholesterol/HDL-cholesterol ratio > 5.0 or if the participant used medication to reduce 
cholesterol. Diabetes was defined as fasting glucose ≥ 126 mg/dL or use of hypoglycemic 
medication. Estimated glomerular filtration rate (eGFR) was computed using the CKD-Epi 
equation.14
Stored fasting blood samples obtained at clinic visits 2 and 3 were analyzed to provide 
serum concentrations of adiponectin, leptin, plasma renin activity and aldosterone. The 
adipokines (leptin and total adiponectin) were measured using Bio-Rad Luminex flow 
cytometry (Millepore, Billerica, MA). Average analytical coefficients of variation across 
several control samples for these analytes ranged from 6.0-13.0%. Plasma renin activity was 
measured using the GammaCoat Plasma Renin Activity 125I radioimmunoassay (RIA) Kit 
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(DiaSorin; Stillwater, MN), while aldosterone was measured using a competition-based 
radioimmunoassay (ALDOCTK-2; Diasorin, Stillwater, MN). The intra-assay coefficients of 
variation for PRA ranged from 6.89 to 18.38% and 6.30 to 8.87% for aldosterone, 
respectively. All assays were performed at the Laboratory for Clinical Biochemistry 
Research (University of Vermont, Burlington, VT).
Statistical Analysis
Among the 1,970 potential participants, there were 81 individuals who were missing values 
for aldosterone and the covariates, resulting in a final analytic sample of 1,889 participants 
available for analysis when aldosterone was the outcome. Similarly, there were 169 
individuals who were missing values for PRA and the covariates leaving a sample size of 
1,801 for these analyses.
Characteristics of the population were described with a mean and standard deviation for 
continuous variables, while categorical variables were summarized as a count and 
percentage of the study population. Multivariable linear regression was used to assess the 
association between adipokines and both PRA and aldosterone (separately). This was done 
using 1-standard deviation increments of the adipokines, as well as categorizing adiponectin 
and leptin into quartiles to assess for potential threshold effects and non-linearity in the 
associations. For all regression analyses, the initial model included adjustments for age, 
gender and race/ethnicity. Models were subsequently adjusted for body mass index (model 
2), diabetes, dyslipidemia, smoking and hypertension medication use (model 3), estimated 
glomerular filtration rate (model 4) and, for when aldosterone was the outcome, PRA (model 
5). To account for the potential confounding due to the effects of central adiposity, we also 
performed the analyses described above but replaced BMI with values for height and the 
waist to hip ratio.
Multiplicative interactions between each adipokine and gender, race/ethnicity and body 
mass index were assessed. A two-tailed p-value < 0.05 was considered statistically 
significant for all analyses, except interaction terms where a p-value < 0.20 was considered 
significant. All statistical analyses were conducted using STATA (Version 11; StataCorp, 
College Station, TX).
RESULTS
The characteristics of the study cohort are provided in Table 1. The mean age of the cohort 
was 64.7 years and 50% were female. Forty percent were non-Hispanic White, 26% were 
Hispanic/Latino, 21% were African American and 13% were Chinese American. The mean 
BMI was 28.2 kg/m2 and 31% had a BMI greater than 30 kg/m2. Most (46%) were never 
smokers, whereas 43% were former smokers and 11% were current smokers. Over half 
(54%) of the participants were hypertensive, 40% were classified as dyslipidemic and 14% 
as having diabetes mellitus. The mean serum creatinine and eGFR were 0.94 mg/dl and 78 
mL/min/1.73 m2, respectively.
In men and women, the mean adiponectin levels were 17.0 and 24.5 μg/ml, while the mean 
values of leptin were 10.8 and 31.1 pg/ml, respectively. The mean values for adiponectin 
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and leptin among the four ethnic groups were as follows: African American: 17.2 μg/ml and 
24.1 pg/ml, Chinese American: 24.1 and 8.5, Hispanic Americans: 20.3 and 18.9, non-
Hispanic White: 22.9 and 17.4, respectively. The correlations between BMI and adiponectin 
were modest and somewhat different between men (r = −0.18, p = 0.01) and women (r = 
−0.25, p = 0.01), while the correlations between BMI leptin were similar and strong for both 
men (r = 0.63, p = 0.01) and women (r = 0.64, p = <0.01). Correlations between BMI and 
both adiponectin and leptin in the different ethnic groups were: African Americans: r = 
−0.19 and 0.58, p < 0.01 for both; Chinese Americans: −0.18 and 0.50, p < 0.01 for both; 
Hispanic Americans: −0.13 and 0.52, p < 0.01 for both; non-Hispanic White: −0.31 and 0.58 
respectively, p < 0.01 for both.
Associations of Adiponectin with Plasma Renin Activity and Aldosterone
With adjustment for age, gender and race/ethnicity, a 1-SD increment of adiponectin was not 
associated with PRA level (β = 0.01 ng/ml, p = 0.85)[Table 2]. Conversely, after the same 
adjustment for age, a 1-SD increment in adiponectin was significantly associated with a 6.0 
pg/ml lower aldosterone level (p < 0.01). In the fully adjusted model, adiponectin remained 
significantly associated with lower aldosterone (β = −5.5, p = 0.01) and the addition of PRA 
minimally changed the association (β = −5.4, p = 0.02). When BMI was replaced by height 
and the waist to hip ratio, adiponectin remained non-significantly associated with PRA (β = 
−0.06, p = 0.46), but significantly associated with lower aldosterone (β = −4.7, p = 0.04).
The results of multivariable linear regression when adiponectin was considered as a 
categorical variable and divided into quartiles are provided in Figures 1 & 2. Compared to 
the lowest quartile and after adjustment for age, gender and race/ethnicity, there were 
modest, non-significant differences in PRA with each higher quartile of adiponectin (Figure 
1), which was not changed after full adjustment. Conversely, after multivariable adjustment, 
there were step-wise increases in the differences in aldosterone with each higher quartile of 
adiponectin (Figure 2). More specifically, compared to the 1st quartile, the 2nd, 3rd and 4th 
quartiles of adiponectin were associated with 9.8 (p = 0.08), 10.7 (p = 0.08) and 22.8 (p < 
0.01) pg/ml lower aldosterone levels. Addition of leptin to the models described above, as 
well as PRA to the models where aldosterone was the outcome, did not materially change 
the findings.
Associations of Leptin with Plasma Renin Activity and Aldosterone
With adjustment for age, gender and race/ethnicity, a 1-SD increment of leptin was 
associated with a 0.57 ng/ml higher PRA level (p < 0.01) [Table 2]. Additional adjustments 
for BMI (β = 0.60, p < 0.01), diabetes, dyslipidemia, smoking and hypertension medication 
use (β = 0.59, p < 0.01) and estimated glomerular filtration rate (β = 0.55, p < 0.01) did not 
materially change the magnitude and significance of the association. Similarly, after 
adjustment for age, gender and race/ethnicity, the same increment in leptin was significantly 
associated with an 8.5 pg/ml higher aldosterone level (p < 0.01). In the fully adjusted model, 
leptin remained significantly associated with higher aldosterone (β = 8.4, p < 0.01), which 
was modestly attenuated when PRA was added (β = 7.2, p < 0.01). When BMI was replaced 
by height and the waist to hip ratio, leptin remained significantly associated with higher 
PRA (β = 0.38, p < 0.01), but not associated with higher aldosterone (β = 3.9, p = 0.12).
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The results of multivariable linear regression when leptin was considered as a categorical 
variable and divided into quartiles are provided in Figures 1 & 2. Compared to the lowest 
quartile and after adjustment for age, gender and race/ethnicity, there was a step-wise 
increase in the differences in PRA with each higher quartile of leptin (Figure 1), which was 
maintained after full adjustment. More specifically, in the final multivariable model, the 2nd, 
3rd and 4th quartiles of leptin were associated with 0.0 (p = 0.92), 0.21 (p = 0.42) and 0.66 (p 
= 0.05) ng/ml higher PRA levels. Likewise, there were step-wise increases in the differences 
in aldosterone with each higher quartile of leptin (Figure 2). That is, compared to the 1st 
quartile, the 2nd, 3rd and 4th quartiles of leptin were associated with 3.3 (p = 0.57), 12.2 
(0.07) and 27.1 (p < 0.01) pg/ml higher aldosterone levels. Addition of adiponectin to the 
models described above, as well as PRA to the models where aldosterone was the outcome, 
did not materially change the findings.
Effect of Antihypertensive Medications
Participants who were on anti-hypertensive medications (n = 1,117) were significantly older 
(67.6 vs. 62.5 years, p < 0.01) and had significantly higher waist (101.6 vs. 95.7 cm, p < 
0.01) and hip circumferences (106.0 vs. 102.9 cm, p < 0.01), body mass index (29.2 vs. 27.3, 
p < 0.01), fasting glucose (102.6 vs. 95.1 mg/dl, p < 0.01), serum creatinine (1.0 vs. 0.9 
mg/dl, p < 0.01), interleukin – 6 (2.6 vs. 2.2 pg/ml, p < 0.01), fibrinogen (446 vs. 427 mg/dl, 
p < 0.01) and resistin (17.5 vs. 15.5 pg/ml, p < 0.01), but significantly lower total (183.7 vs. 
194.3 mg/dl, p < 0.01) and HDL (50.6 vs. 52.0 mg/dl, p < 0.05) cholesterol levels. Those on 
these medications were also more likely to be African American (p < 0.01), diabetic or a 
former smoker, as well as being on a cholesterol lowering medication (p < 0.01 for all), but 
were not significantly different by gender or CRP level.
Among those not taking an anti-hypertensive medication and after adjustment for age, 
gender and race/ethnicity, a 1-SD increment in adiponectin was not significantly associated 
with PRA level (−0.07 ng/ml, p = 0.18). This association remained non-significant after full 
adjustment (-0.03 ng/ml, p = 0.56) and the results were not materially different when 
adiponectin was categorized into quartiles (Figure 1). On the other hand, a 1-SD increment 
in adiponectin was associated with significantly lower aldosterone levels (−6.7 pg/ml, p < 
0.01), which was modestly changed with full adjustment (−5.3 pg/ml, p = 0.05). 
Categorizing adiponectin into quartiles revealed a step-wise association with aldosterone 
(Figure 2).
For leptin, 1-SD increment was associated with significantly higher PRA (0.12 ng/ml, p = 
0.03), which was not remarkably changed with full adjustment (0.13 ng/ml, p = 0.06). 
Analyses utilizing quartiles of leptin revealed that those in the highest quartile (Q4) drove 
this association, where PRA levels were 0.17 ng/ml higher than those in the first quartile 
(Figure 1). Conversely, a 1-SD increment in leptin was not significantly associated with 
higher aldosterone (4.0 pg/ml, p = 0.23). Categorizing leptin into quartiles revealed a step-
wise increases in aldosterone (Figure 2). While potentially clinically relevant, none were 
statistically significantly different from the value for those in the first quartile.
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Differences in the Associations by Gender and Race/Ethnicity
Using multiplicative interaction terms, we tested for significant differences in the 
magnitudes of the associations between both adiponectin and leptin for PRA and aldosterone 
(separately) by gender and then race/ethnicity. There were no significant interactions 
between gender and either adiponectin or leptin for PRA or aldosterone. Similarly, there 
were no significant interactions between race/ethnicity and adiponectin for either PRA or 
aldosterone. However, there was a significant interaction between race/ethnicity and leptin 
for PRA (p < 0.01), as well as aldosterone (p < 0.01) [Table 3]. After adjustment for age, 
gender, BMI, diabetes, dyslipidemia, smoking, hypertension medication use and estimated 
glomerular filtration rate, a 1-SD increment in leptin was associated with 1.74 ng/ml higher 
PRA level among non-Hispanic Whites (p < 0.01), 0.95 higher among Chinese Americans 
(p < 0.01) and 0.15 higher among Hispanic Americans (p = 0.39), but a 0.13 lower PRA 
among African Americans (p = 0.39). The findings were similar for the associations between 
leptin and aldosterone. Specifically, a 1-SD increment in leptin was associated with 15.9 (p 
< 0.01) and 14.9 (p = 0.15) pg/ml higher aldosterone for non-Hispanic Whites and Chinese 
Americans respectively, while being 6.0 (p = 0.17) and 4.0 (p = 0.45) pg/ml higher among 
African and Hispanic Americans.
Effect Modification by Body Mass Index
The mean levels of leptin and adiponectin were significantly different by BMI group. For 
BMI values of 18.5 – 25, 25 – 30, 30 – 35 and > 35 kg/m2, mean concentrations of 
adiponectin were 24.9, 19.8, 18.1 and 16.0 μg/ml, while mean leptin concentrations were 
8.9, 17.1, 34.5 and 57.6 ng/ml, respectively.
There were no significant multiplicative interactions between either adiponectin or leptin 
with BMI group for PRA. Conversely, there were significant interactions between 
adiponectin (p = 0.17) and leptin (p < 0.01) with BMI group for aldosterone (Figure 3). In 
multivariable linear regression analyses, a 1-SD increment in adiponectin was associated 
with 2.5 pg/ml higher aldosterone among those with a BMI between 18.5 and 25, while for 
those with BMI values between 25 and 30, 30 and 35 and greater than 35, the same 
increment of adiponectin was associated with −3.2, −9.5 and −23.4 pg/ml, respectively, 
lower aldosterone concentrations. On the other hand, a 1-SD increment of leptin was 
associated with 8.2, 9.5, 2.9 and 1.3 pg/ml, respectively, higher aldosterone concentrations. 
When those on anti-hypertensive therapy were removed from the analysis, the results were 
similar.
DISCUSSION
In this study of a large, multi-ethnic population-based cohort from multiple sites across the 
United States, higher leptin concentrations were associated with significantly higher levels 
of both PRA and aldosterone while higher adiponectin concentrations were significantly 
associated with lower levels of aldosterone only. For both adipokines, the significance of the 
associations was independent of relevant covariates to include measures of total and central 
adiposity. Notably, the association between both adipokines and aldosterone remained 
significant after additional adjustment for PRA. Moreover, among those not taking any anti-
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hypertensive medications, the magnitudes of the associations between adiponectin and leptin 
and both PRA and aldosterone were attenuated but similar in pattern to those for the entire 
cohort. Additionally, there was a significant interaction between leptin and race/ethnicity for 
both PRA and aldosterone, whereby, compared to African- and Hispanic Americans, the 
magnitudes of these associations were significantly larger among non-Hispanic Whites and 
Chinese Americans. Finally, the associations between both adipokines and aldosterone were 
significantly different by BMI group. Taken together, the findings from this study suggest 
that both adiponectin and leptin may be related to blood pressure regulation via the RAAS, 
that the associations appear to be robust to anti-hypertension medication use and that the 
associations are likely different by ethnicity and BMI group.
In all forms of hypertension, there is a shift in renal pressure natriuresis to a higher blood 
pressure level resulting in sodium retention and expanded plasma volume.17,18 This change 
in sodium reabsorption may be due to the direct effects of SNS activity on the proximal and 
distal renal tubules, stimulation of the RAAS or both. 19 In this regard, a major determinant 
of SNS activity is the amount of excess adipose tissue.10,20 Since leptin is derived 
principally from this tissue type, higher levels of adiposity can result in chronically higher 
leptin levels. Also, leptin has been shown to stimulate the region of the hypothalamus that 
regulates SNS outflow to the periphery.8,21 According to the model just described, the 
higher levels of adiposity associated with obesity could result in a chronic increase SNS 
activity due to the hypothalamic stimulatory effects of leptin and that may be manifest by 
higher levels of both renin and aldosterone. Our results are consistent with this paradigm.
Despite the highest prevalence of hypertension of any racial/ethnic group, 22 African 
Americans are known to have lower levels of renin, 23 which has led to the hypothesis that 
the RAAS does not play a significant causative role in hypertension in this group. More 
specifically, increased sympathetic tone among African Americans may not result in the 
same elevations in RAAS markers as among other ethnic groups. As such, blood pressure 
elevation may be attributable to overload and an increased sensitivity to sodium ingestion 
that both lowers RAAS activity and causes hypertension. 24 The findings of our study are 
consistent with this paradigm. That is, despite leptin levels that were higher than those for 
the other 3 ethnic groups, the association between leptin and renin was null and not 
significant among African Americans while being significant for non-Hispanic Whites and 
Chinese Americans.
An interesting finding from our study is that the association between leptin and aldosterone 
was significantly different by BMI group. Specifically, the magnitude of the association 
between leptin and aldosterone decreased when BMI was in the obese range and suggests 
that the influence of leptin on aldosterone levels may be attenuated at higher levels of 
adiposity. This is consistent with the hypothesized concept of leptin resistance25, which is 
similar to that for insulin whereby, despite higher levels of leptin, the effects are diminished. 
In this regard, previous studies in animal models demonstrate attenuation of the metabolic, 
but not autonomic nervous system, effects of leptin with higher levels of obesity.3,5,26 More 
specifically, the effects of leptin on free fatty acid uptake and oxidation in skeletal muscle 
are diminished while stimulation of the sympathetic nervous system remains seemingly 
unchanged. Moreover, reports on the association between leptin and left ventricular mass 
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show an inverse association among those with a BMI with the normal to overweight 
range27-29, but a positive association in those who are obese.26
Contrasted with the associations between leptin and both PRA and aldosterone, higher 
adiponectin levels were only significantly [and inversely] associated with aldosterone, which 
remained after adjustment for both leptin and PRA. Like leptin, adiponectin is secreted 
primarily by adipose tissue, but, unlike leptin, increasing adiposity typically results in lower 
levels of adiponectin.30 Of note, previous studies have shown that aldosterone can reduce 
adiponectin either directly or by increasing TNF-α, which also decreases levels of 
adiponectin.30,31 Moreover, Li and colleagues have shown that aldosterone and TNF-alpha 
act synergistically to lower adiponectin levels.4,32 Since increasing SNS stimulation results 
in higher levels of angiotensinogen and angiotensin II33, and this results in higher 
aldosterone levels, it is plausible that the SNS stimulation present in those with obesity-
associated hypertension will result in lower adiponectin levels due to higher levels of 
aldosterone. If true, rather than stimulating the RAAS [as is hypothesized for leptin], it 
would seem that higher adiponectin is the result of upregulation of downstream RAAS 
components.
Perhaps unexpectedly, the associations between both adiponectin and leptin with aldosterone 
were independent of PRA. This suggests that there may be an alternative pathway that does 
not include renin and that results in higher levels of aldosterone. In this respect, it has been 
demonstrated that, in addition to expressing adiponectin and leptin, adipose tissue can 
release angiotensinogen and angiotensin II, both of which are stimulates of aldosterone 
release.34 As such, one would expect that, with increasing adiposity, increases in aldosterone 
could parallel to the appropriate changes for adiponectin and leptin and be due to stimulation 
by angiotensinogen and/or angiotensin II.
Strengths of this study include a large, multi-ethnic cohort that allowed for comparison of 
associations across gender, ethnicity, body mass index and anti-hypertension medication 
use, as well as very reproducible assays of both adiposity-associated inflammation and 
selected markers of the renin-angiotensinogen-aldosterone system affording the opportunity 
to test the study aims. The primary limitation is the cross-sectional study design that 
precludes elimination of reverse causality as a potential source of error in the interpretation 
of the results. As such, longitudinal studies of these measures seem warranted.
In conclusion, adiponectin and leptin are significantly associated with markers of the renin-
angiotensin-aldosterone system and these measures appear to be robust across anti-
hypertension medication use, as well as being different by ethnicity and body mass index 
groups. The findings for leptin suggest that this adipokine may contribute to higher levels of 
both renin and aldosterone via activation of the sympathetic nervous system, while lower 
adiponectin may be due to higher levels of aldosterone that is a result of the increasing 
adiposity of obesity. Confirmation of these claims by longitudinal studies is recommended.
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SUMMARY TABLE
What is Known About the Topic:
- Previous studies have demonstrated a robust association between greater adipose tissue 
and higher levels of blood pressure, as well as incident hypertension.
- Although undoubtedly a multifactorial phenomenon, hypertension in obese individuals 
has been linked with activation of the renin-angiotensinogen-aldosterone system (RAAS) 
and plasma volume expansion.
- In this regard, higher sympathetic nervous system (SNS) activity, present in obese 
individuals, results in increased renin release, aldosterone production, and renal tubular 
sodium reabsorption.
- However, the pathophysiologic links between excess adiposity and higher blood 
pressure are incompletely understood.
What this Study Adds:
- The findings of this study indicate that both leptin and adiponectin are significantly 
associated with markers of the renin-angiotensinogen-aldosterone system.
- In the case of adiponectin, the associations are independent of plasma renin activity 
levels.
- These associations are not materially different among those not taking blood pressure 
medications and there are differences by ethnicity, as well as levels of adiposity.
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FIGURE 1. DIFFERENCES IN LEVELS OF PLASMA RENIN ACTIVITY BY QUARTILES 
OF LEPTIN AND ADIPONECTIN
Referent Category = Quartile 1; Q2 = 2nd Quartile, Q3 = 3rd Quartile, Q4 = 4th Quartile 
Adjusted for age, gender, race/ethnicity, body mass index, diabetes, dyslipidemia, smoking 
and estimated glomerular filtration rate
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FIGURE 2. DIFFERENCES IN LEVELS OF ALDOSTERONE BY QUARTILES OF LEPTIN 
AND ADIPONECTIN
Referent Category = Quartile 1; Q2 = 2nd Quartile, Q3 = 3rd Quartile, Q4 = 4th Quartile 
Adjusted for age, gender, race/ethnicity, body mass index, diabetes, dyslipidemia, smoking 
and estimated glomerular filtration rate
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FIGURE 3. ASSOCIATIONS BETWEEN ALDOSTERONE AND BOTH ADIPONECTIN AND 
LEPTIN BY BODY MASS INDEX GROUP
Adjusted for age, gender, race/ethnicity, body mass index, diabetes, dyslipidemia, smoking, 
estimated glomerular filtration rate and plasma renin activity *Per SD increment in Leptin 
(22.3 ng/ml) and Adiponectin (13.2 μg/ml) within each BMI strata
Allison et al. Page 15
J Hum Hypertens. Author manuscript; available in PMC 2015 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Allison et al. Page 16
TA
B
LE
 1
CO
H
O
RT
 C
H
A
RA
CT
ER
IS
TI
CS
C
ha
ra
ct
er
ist
ic
M
ea
n 
(S
D)
/M
ed
ian
 or
 Fr
eq
ue
nc
y (
%
)
A
ge
 (y
ea
rs)
64
.7
 (9
.7)
/64
.5
G
en
de
r (
ma
le)
98
7 
(50
)
R
ac
e
 
 
 
 
-
 
N
on
-H
isp
an
ic
 W
hi
te
79
1 
(40
.0)
 
 
 
 
-
 
Ch
in
es
e 
A
m
er
ic
an
25
9 
(13
.1)
 
 
 
 
-
 
A
fri
ca
n 
A
m
er
ic
an
41
2 
(20
.9)
 
 
 
 
-
 
H
isp
an
ic
 A
m
er
ic
an
51
4 
(26
.0)
H
ei
gh
t (
cm
)
16
6.
4 
(9.
9)/
16
6.4
W
ai
st 
ci
rc
um
fe
re
nc
e 
(cm
)
98
.3
 (1
4.2
)/9
7
H
ip
 c
irc
um
fe
re
nc
e 
(cm
)
10
4.
4 
(10
.9)
/10
2.8
B
M
I (
kg
/m
2)
28
.2
 (5
.2)
/27
.4
W
ai
st 
to
 H
ip
 R
at
io
0.
94
 (0
.07
)/0
.94
To
ta
l C
ho
le
ste
ro
l (
mg
/dl
)
18
9.
6 
(35
.5)
/18
8
H
D
L 
Ch
ol
es
te
ro
l (
mg
/dl
)
51
.5
 (1
5.2
)/4
9
Ch
ol
es
te
ro
l M
ed
ic
at
io
n 
U
se
48
1 
(25
.1)
D
ys
lip
id
em
ia
78
4 
(39
.9)
G
lu
co
se
 (m
g/d
l)
98
.3
 (2
7.7
)/9
1
D
ia
be
te
s
28
3 
(14
.4)
Ci
ga
re
tte
 S
m
ok
in
g
 
 
 
 
-
 
Cu
rre
nt
22
8 
(11
.6)
 
 
 
 
-
 
Fo
rm
er
84
1 
(42
.6)
 
 
 
 
-
 
N
ev
er
90
4 
(45
.8)
Sy
sto
lic
 B
lo
od
 P
re
ss
ur
e 
(m
mH
g)
12
4 
(20
.8)
/12
1
D
ia
sto
lic
 B
lo
od
 P
re
ss
ur
e 
(m
mH
g)
70
.8
 (9
.9)
/69
.5
H
yp
er
te
ns
io
n
10
68
 (5
4)
Ca
lib
ra
te
d 
Cr
ea
tin
in
e 
(m
g/d
l)
0.
96
 (0
.27
)/0
.92
Ca
lib
ra
te
d 
eG
FR
 (m
L/
mi
n/1
.73
 m
2 )
77
.6
 (1
7.3
)/7
8.1
J Hum Hypertens. Author manuscript; available in PMC 2015 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Allison et al. Page 17
C
ha
ra
ct
er
ist
ic
M
ea
n 
(S
D)
/M
ed
ian
 or
 Fr
eq
ue
nc
y (
%
)
A
di
po
ne
ct
in
 (μ
g/m
l)
20
.7
 (1
3.2
)/1
7.4
Le
pt
in
 (n
g/m
l)
20
.9
 (2
2.3
)/1
3.5
R
en
in
 (n
g/m
l)
1.
45
 (3
.3)
/0.
56
A
ld
os
te
ro
ne
 (p
g/m
l)
15
0.
1 
(86
.9)
/13
0.5
J Hum Hypertens. Author manuscript; available in PMC 2015 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Allison et al. Page 18
TA
B
LE
 2
M
U
LT
IV
A
RI
A
BL
E 
LI
N
EA
R 
RE
G
RE
SS
IO
N
 O
F 
A
D
IP
O
N
EC
TI
N
 A
N
D
 L
EP
TI
N
 F
O
R 
PL
A
SM
A
 R
EN
IN
 A
CT
IV
IT
Y
 A
N
D
 A
LD
O
ST
ER
O
N
E
PL
A
SM
A
 R
EN
IN
 A
C
TI
V
IT
Y
 (P
RA
)
A
di
po
ne
ct
in
M
od
el
 1
M
od
el
 2
M
od
el
 3
M
od
el
 4
Le
pt
in
M
od
el
 1
M
od
el
 2
M
od
el
 3
M
od
el
 4
β 
sig
β 
sig
β 
sig
β 
sig
β 
sig
β 
sig
β 
sig
β 
sig
Co
nt
in
uo
us
 (1
-S
D)
*
0.
01
0.
85
0.
09
0.
32
0.
07
0.
41
0.
04
0.
60
Co
nt
in
uo
us
 (1
-S
D)
0.
57
<
0.
01
0.
60
<
0.
01
0.
59
<
0.
01
0.
55
<
0.
01
Ca
te
go
ric
al
*
*
Ca
te
go
ric
al
*
-
 
 
 
 
 
Qu
art
ile
 2
−
0.
29
0.
20
−
0.
23
0.
32
−
0.
13
0.
55
−
0.
13
0.
57
-
 
 
 
 
 
Qu
art
ile
 2
0.
27
0.
23
0.
22
0.
34
0.
01
0.
95
−
0.
02
0.
92
-
 
 
 
 
 
Qu
art
ile
 3
−
0.
13
0.
58
0.
02
0.
92
0.
19
0.
42
0.
20
0.
39
-
 
 
 
 
 
Qu
art
ile
 3
0.
57
0.
02
0.
49
0.
07
0.
29
0.
28
0.
21
0.
42
-
 
 
 
 
 
Qu
art
ile
 4
0.
02
0.
91
0.
27
0.
28
0.
40
0.
11
0.
32
0.
20
-
 
 
 
 
 
Qu
art
ile
 4
1.
12
<
0.
01
0.
96
<
0.
01
0.
76
0.
03
0.
66
0.
05
A
LD
O
ST
ER
O
N
EE
A
di
po
ne
ct
in
M
od
el
 1
M
od
el
 2
M
od
el
 3
M
od
el
 4
Le
pt
in
M
od
el
 1
M
od
el
 2
M
od
el
 3
M
od
el
 4
β 
sig
β 
sig
β 
sig
β 
sig
β 
sig
β 
sig
β 
sig
β 
sig
Co
nt
in
uo
us
 (1
-S
D)
*
−
6.
0
<
0.
01
−
5.
7
0.
01
−
5.
1
0.
02
−
5.
5
0.
01
Co
nt
in
uo
us
 (1
-S
D)
8.
5
<
 0
.0
1
10
.7
<
0.
01
9.
3
<
0.
01
8.
4
<
0.
01
Ca
te
go
ric
al
*
*
Ca
te
go
ric
al
*
-
 
 
 
 
 
Qu
art
ile
 2
−
8.
1
0.
16
−
8.
0
0.
16
−
10
.0
0.
08
−
9.
8
0.
08
-
 
 
 
 
 
Qu
art
ile
 2
6.
5
0.
26
9.
0
0.
13
4.
3
0.
46
3.
3
0.
57
-
 
 
 
 
 
Qu
art
ile
 3
−
12
.8
0.
03
−
12
.7
0.
03
−
11
.2
0.
06
−
10
.7
0.
08
-
 
 
 
 
 
Qu
art
ile
 3
14
.3
0.
02
19
.2
<
0.
01
14
.2
0.
03
12
.2
0.
07
-
 
 
 
 
 
Qu
art
ile
 4
−
23
.6
<
0.
01
−
23
.4
<
0.
01
−
21
.8
<
0.
01
−
22
.8
<
0.
01
-
 
 
 
 
 
Qu
art
ile
 4
27
.7
<
0.
01
37
.1
<
0.
01
29
.8
<
0.
01
27
.1
<
0.
01
β =
 p
ar
am
et
er
 e
sti
m
at
e,
 S
ig
 =
 L
ev
el
 o
f s
ig
ni
fic
an
ce
 (p
-va
lue
)
M
od
el
 1
: A
ge
, g
en
de
r, 
ra
ce
/e
th
ni
ci
ty
; M
od
el
 2
: M
od
el
 1
 +
 b
od
y 
m
as
s i
nd
ex
; M
od
el
 3
: M
od
el
 2
 +
 D
ys
lip
id
em
ia
 +
 D
ia
be
te
s +
 S
m
ok
in
g 
+ 
H
TN
 M
ed
s; 
M
od
el
 4
: M
od
el
 3
 +
 c
re
at
in
in
e
*
St
an
da
rd
 D
ev
ia
tio
ns
: L
ep
tin
 =
 2
2.
3 
ng
/m
l, 
A
di
po
ne
ct
in
 =
 1
3.
2 
μg
/m
l
*
*
Qu
art
ile
 C
ut-
po
int
s: 
Le
pti
n –
 Q
1: 
< 4
.47
, Q
2: 
4.4
7 –
 11
.14
, Q
3: 
11
.14
 – 
24
.77
, Q
4: 
> 2
4.7
7; 
Ad
ipo
ne
cti
n: 
Q1
: <
 11
.82
, Q
2: 
11
.82
 – 
17
.52
, Q
3: 
17
.52
 -2
6.3
2, 
Q4
: >
 26
.32
 U
nit
s: 
PR
A 
(ng
/m
l),
 A
ldo
ste
ron
e 
(pg
/m
l)
J Hum Hypertens. Author manuscript; available in PMC 2015 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Allison et al. Page 19
TA
B
LE
 3
D
IF
FE
R
EN
CE
S 
IN
 T
H
E 
A
SS
O
CI
A
TI
O
N
S 
BE
TW
EE
N
 L
EP
TI
N
 A
N
D
 B
O
TH
 P
LA
SM
A
 R
EN
IN
 A
CT
IV
IT
Y
 A
N
D
 A
LD
O
ST
ER
O
N
E 
BY
 E
TH
N
IC
 
G
RO
U
P
R
ac
e/
Et
hn
ic
ity
Sa
m
pl
e S
iz
e (
N)
R
EN
IN
A
LD
O
ST
ER
O
N
E
Es
tim
at
e
p-
va
lu
e
Es
tim
at
e
p-
va
lu
e
N
on
-H
isp
an
ic
 W
hi
te
69
9
1.
74
<
0.
01
15
.9
<
0.
01
Ch
in
es
e 
A
m
er
ic
an
23
3
0.
95
<
0.
01
14
.9
0.
15
A
fri
ca
n 
A
m
er
ic
an
32
5
−
0.
13
0.
39
6.
0
0.
17
H
isp
an
ic
 A
m
er
ic
an
49
9
0.
15
0.
39
4.
0
0.
45
A
dju
ste
d f
or 
ag
e, 
ge
nd
er,
 ra
ce/
eth
nic
ity
, b
od
y m
ass
 in
de
x, 
dia
be
tes
, d
ysl
ipi
de
mi
a, 
sm
ok
ing
 an
d h
yp
ert
en
sio
n m
ed
ica
tio
n u
se,
 es
tim
ate
d g
lom
eru
lar
 fil
tra
tio
n r
ate
*
 P
er
 S
D
 in
cr
em
en
t i
n 
Le
pt
in
 (2
2.3
 ng
/m
l) 
an
d A
dip
on
ec
tin
 (1
3.2
 μg
/m
l) 
wi
thi
n e
ac
h r
ac
ial
 gr
ou
p
J Hum Hypertens. Author manuscript; available in PMC 2015 August 01.
